Drug evaluation and the permissive principle: Continuities and contradictions between standards and practices in antidepressant regulation

Social Studies of Science

Volumn 39, Issue 4, 2009, Pages 569-598

  Abraham, John ^a   Davis, Courtney ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

Clinical trials; Drug efficacy; FDA; Regulatory science; UK regulation

Indexed keywords

ANTIDEPRESSANT AGENT;

ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG APPROVAL; DRUG CONTROL; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; HISTORY; HUMAN; UNITED KINGDOM; UNITED STATES;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DEPRESSION; DRUG AND NARCOTIC CONTROL; DRUG APPROVAL; DRUG EVALUATION; GREAT BRITAIN; HISTORY, 20TH CENTURY; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 69549083387     PISSN: 03063127     EISSN: 14603659     Source Type: Journal    
DOI: 10.1177/0306312709103480     Document Type: Article

References (85)

1. Abraham, John (1993) Scientific Standards and Institutional Interests: Carcinogenic Risk Assessment of Benoxaprofen in the UK and US, Social Studies of Science 23: 387-444.
2. Abraham, John (1995a) 'The Production and Reception of Scientific Papers in the Academic-Industrial Complex', British Journal of Sociology 46: 167-90.
3. Abraham, John (1995b) Science, Politics and the Pharmaceutical Industry: Controversy and Bias in Drug Regulation (London/New York: UCL/St Martins Press Press).
4. Abraham, John (1997) The Science and Politics of Medicines Regulation, in M.A. Elston (ed.), Sociology of Medical Science and Technology (Oxford: Blackwell): 153-82.
5. Abraham, John (1998) Regulating the Cancer-inducing Potential of Non-steroidal Antiinflammatory Drugs, Social Science & Medicine 46: 39-51.
6. Abraham, John (2007) From Evidence to Theory: Neo-liberal Corporate Bias as a Framework for Understanding UK Pharmaceuticals Regulation, Social Theory & Health 5: 161-75.
7. Abraham, John & Courtney Davis (2005) A Comparative Analysis of Drug Safety Withdrawals in the UK and the US, Social Science & Medicine 61: 881-92.
8. Abraham, John & Courtney Davis (2007) Interpellative Sociology of Pharmaceuticals, Technology Analysis & Strategic Management 19: 387-402.
9. Abraham, John & Graham Lewis (2000) Regulating Medicines in Europe: Competition, Expertise and Public Health (London/New York: Routledge/Taylor & Francis).
10. Abraham, John & Tim Reed (2002) Progress, Innovation and Regulatory Science in Drug Development: The Politics of International Standard-setting, Social Studies of Science 32: 337-69.
11. Abraham, John & Julie Sheppard (1999) The Therapeutic Nightmare; The Battle over the World's most Controversial Sleeping Pill (London: Earthscan).
12. Andersson, Fredrick (1992) The Drug Lag Issue, International Journal of Health Services 22: 53-72.
13. Angell, Marcia (2004) The Truth About the Drug Companies (New York: Random House).
14. Anonymous (1985) Nomifensine UK Data Sheet Change, Scrip 1047 (October 30): 23.
15. Anonymous (1986) Hoescht withdraws Nomifensine, Scrip 1072 (January 29): 22-23.
16. Armstrong, David (2002) Clinical Autonomy, Individual and Collective, Social Science & Medicine 55: 1771-77.
17. Association of the British Pharmaceutical Industry (1984a) Dr John Griffin Takes over as ABPI Chief, ABPI News 198: 1.
18. Association of the British Pharmaceutical Industry (1984b) New ABPI Director Stresses Importance of Two-way Flow between Medicines Division and Industry, ABPI News 198: 3.
19. Bal, Roland (1998) Boundary Dynamics in Dutch Standard-Setting for Occupational Chemicals, in R. Bal & W. Halffman (eds), The Politics of Chemical Risk (Dordrecht: Kluwer): 75-103.
20. Boseley, Sarah. (2006) Antidepressant Linked to Suicide Risk in Adults, Guardian (13 May).
21. Brickman, Ronald, Sheila Jasanoff, & Tom Ilgen (1985) Controlling Chemicals: The Politics of Regulation in Europe and the US (Ithaca, NY: Cornell University Press).
22. British Journal of Clinical Pharmacology (1977) 'Nomifensine', British Journal of Clinical Pharmacology 4 (Suppl. 2) (Proceedings of a Symposium held in London in January 1977).
23. Brogden, R.N., R.C. Heel, T.M. Speight & G.S. Avery (1979) Nomifensine: A Review of its Pharmacological Properties and Therapeutic Efficacy in Depressive Illness, Drugs 18: 1-24.
24. Brown, Nick & Andrew Webster (2004) New Medical Technologies and Society (Cambridge: Polity).
25. Cambrosio, Alberto, Peter Keating, Thomas Schlich & George Weisz (2006) Regulatory Objectivity and the Generation and Management of Evidence in Medicine, Social Science & Medicine 63: 189-99.
26. Collier, Joe (1989) The Health Conspiracy (London: Century).
27. Cromie, Brian.J. (1980) Testing New Drugs in the UK, Journal of the Royal Society of Medicine 73: 379-80.
28. Daemmrich, Arthur A. (2004) Pharmacopolitics: Drug Regulation in the United States and Germany (Chapel Hill, NC: University of North Carolina Press).
29. David, Matthew (2005) Science in Society (Basingstoke, Hants: Palgrave).
30. Delamothe, T. (1989) 'Drugs Watchdogs and the Drug Industry', British Medical Journal 299: 476.
31. Deuten, Jasper J., Arie Rip & Jaap Jelsma (1997) Societal Embedding and Product Creation Management, Technology Analysis and Strategic Management 9: 131-48.
32. Epstein, Steven (1996) Impure Science: AIDS Activism and the Politics of Knowledge (Berkeley, CA, & London: University of California Press).
33. Faulkner, Alex & Julie Kent (2001) Innovation and Regulation in Human Implant Technologies, Social Science & Medicine 53: 895-913.
34. Fishman, Jennifer R. (2004) Manufacturing Desire: The Commodification of Female Sexual Dysfunction, Social Studies of Science 34: 187-218.
35. Food and Drug Administration (1986) Summary of Significant Accomplishments and Activities in 1985 (Rockville, MD: Food and Drug Administration).
36. Food and Drug Administration (1997) FDA Modernization Act. Section 506(b)(3) of the Food, Drug and Cosmetic Act, amended by section 112 of FDAMA.
37. Geels, Frank W., Toine Pieters & Stephen Snelders (2007) Cultural Enthusiasm, Resistance and the Societal Embedding of New Technologies, Technology Analysis and Strategic Management 19: 145-65.
38. Grabowski, H., J. Vernonand & L. Thomas (1978) Estimating the Effects of Regulation on Innovation, Journal of Law and Economics 21: 133-63.
39. Habermann, W. (1977) A Review of Controlled Studies with Nomifensine, Performed Outside the UK, British Journal of Clinical Pharmacology 4 SUPPL. 2: 237S-242S.
40. Healy, David (1997) The Anti-depressant Era (Cambridge, MA: Harvard University Press).
41. Healy, David (2004a) Shaping the Intimate: Influence on the Experience of Everyday Nerves, Social Studies of Science 34: 219-46.
42. Healy, David (2004b) Let Them Eat Prozac: The Unhealthy Relationship between the Pharmaceutical Industry and Depression (London: New York University Press).
43. Hoescht (1977) Merital Product Data Sheet. London: ABPI Compendium.
44. Hoffman, I. (1977) A Comparative Review of the Pharmacology of Nomifensine, British Journal of Clinical Pharmacology 4: 69S-75S.
45. House of Commons (2005) The Influence of the Pharmaceutical Industry, Health Select Committee Fourth Report of Session 2004-05
46. Jasanoff, Sheila (2005) Designs on Nature: Science and Democracy in Europe and the United States (Princeton, NJ: Princeton University Press).
47. Jenner, F.A. (1977) Some of the Problems and Difficulties Associated with Clinical Studies of Antidepressant Agents, British Journal of Clinical Pharmacology 4 (Suppl. 2): 199S-207S.
48. Keating, Peter & Alberto Cambrosio (2007) Cancer Clinical Trials, Bulletin for the History of Medicine 81: 197-223.
49. Kirsch, I., B.J. Deacon, T.B. Huedo-Medina, A. Scoboria, T.J. Moore, B.T. Johnson (2008) Initial Severity and Antidepressant Benefits, PloS 5: 0260-68.
50. Klein, Hans K. & Daniel Lee Kleinman (2002) The Social Construction of Technology: Structural Considerations, Science, Technology, & Human Values 27: 28-52.
51. Kline, N.S. (1958) Clinical Experience with Iproniazid, Journal of Clinical and Experimental Psychopathology 19 (Suppl. 1): 72-78.
52. Lakoff, Andrew (2005) Pharmaceutical Reason: Knowledge and Value in Global Psychiatry (Cambridge: Cambridge University Press).
53. Latour, Bruno (1999) On Recalling ANT, in J. Law & J. Hassard (eds), Actor Network Theory and After (Oxford: Blackwell): 15-25.
54. Law, John (1999) After ANT, in J. Law & J. Hassard (eds), Actor Network Theory and After (Oxford: Blackwell): 1-14.
55. Lee, H. (1979) FDA Review and Evaluation of Clinical Data, Original NDA (Nomifensine), 14 September.
56. Lee, H. (1980) FDA Review and Evaluation of Clinical Data, NDA Resubmission (Nomifensine), 1 October.
57. Lee, H. (1982) FDA Memo, Nomifensine, 29 September.
58. Marks, Harry M. (1997) The Progress of Experiment: Science and Therapeutic Reform in the US, 1900-1990 (Cambridge: Cambridge University Press).
59. Mirowski, Phillip & Robert Van Horn (2005) The Contract Research Organization and the Commercialization of Scientific Research, Social Studies of Science 35: 503-48.
60. Montgomery, Stuart A. (1982) The Nonselective Effect of Selective Antidepressants, in E. Costa & G. Racagni (eds), Typical and Atypical Antidepressants (New York: Raven Press).
61. Montgomery, Stuart, D. Roy & D.B. Montgomery (1982) Supersensitivity and Nomifensine in Depressed Patients, in E. Costa & G. Racagni (eds), Typical and Atypical Antidepressants (New York: Raven Press).
62. Moore, Tom J. (1995) Deadly Medicine:Why Tens of Thousands of Heart Patients Died in America's Worst Drug Disaster (New York: Simon & Schuster).
63. Moynihan, Roy & A. Cassels (2005) Selling Sickness: How Drug Companies are Turning Us All into Patients (Crows Nest, NSW: Allen & Unwin).
64. Murphy, Joseph, Les Levidow & Susan Carr (2006) Regulatory Standards for Environmental Risks: Understanding the US-European Union Conflict over Genetically Modified Crops, Social Studies of Science 36: 133-60.
65. Parthasarathy, Shobita (2005) Architectures of Genetic Medicine: Comparing Genetic Testing for Breast Cancer in the USA and UK, Social Studies of Science 35: 5-40.
66. Psychopharmacological Drugs Advisory Committee (1979) Transcript, Psychopharmacological Drugs Advisory Committee Meeting, FDA, Rockville, MD, 15 October.
67. Psychopharmacological Drugs Advisory Committee (1983) Transcript, Psychopharmacological Drugs Advisory Committee Meeting, FDA, Rockville, MD, 25 February.
68. Rasmussen, Nicholas (2004) The Moral Economy of the Drug Company-Medical Scientist Collaboration in Interwar America, Social Studies of Science 34: 161-86.
69. Rasmussen, Nicholas (2006) Making the First Antidepressant, Journal of the History of Medicine and Allied Sciences 61: 288-323.
70. Salter, Liora (1988) Mandated Science: Science and Scientists in the Making of Standards (Dordrecht: Kluwer).
71. Schacht, U. & W. Heptner (1974) Effect of Nomifensine (HOE 984), a New Antidepressant, on Uptake of Noradrenaline and Serotonin and on Release of Noradrenaline in Rat Brain Synaptosomes, Biochemical Pharmacology 23: 3413-22.
72. Schildkraut, J.J. (1965) The Catecholamine Hypothesis of Affective Disorders, American Journal of Psychiatry 122: 509-22.
73. Spencer, P.S.J. (1977) Review of the Pharmacology of Existing Anti-depressants, British Journal of Clinical Pharmacology 4: 57S-68S.
74. Spencer, P.S.J., J.P. Gonzalez & R.D.E. Sewell (1984) Nomifensine Pharmacology - A Brief Overview, in W. Linford-Rees & R.G. Priest (eds), Nomifensine: A Pharmacological and Clinical Profile (London: Royal Society of Medicine): 1-6.
75. Stonier, Peter D. & F.A. Jenner (eds) (1980) Nomifensine (London: Royal Society of Medicine, Academic Press, and Grune & Stratton).
76. Taeuber, K. (1977) Comparison of Nomifensine and Placebo, British Journal of Clinical Pharmacology 4 SUPPL. 2: 209S-214S.
77. Temple, Robert & Susan S. Ellenberg (2000) Placebo-controlled Trials and Active-control Trials in the Evaluation of New Treatments, Annals of Internal Medicine 133: 455-63.
78. Turner, E., A.M. Matthews, E. Linardatos, R.A. Tell, R. Rosenthal (2008) Selective Publication of Antidepressant Trials and its Influence on Apparent Efficacy, New England Journal of Medicine 358: 252-60.
79. US Congress (1979) Competitive Problems in the Pharmaceutical Industry, Hearings before a Subcommittee of the Senate Select Committee on Small Businesses 92nd Congress, 10 May (Washington: US Government Printing Office).
80. US Congress (1986) Oversight of the New Drug Review Process, Hearings before a Subcommittee of the Committee on Government Operations. House of Representatives 99th Congress, 22 May (Washington: US Government Printing Office).
81. US Congress (1987) Fifteenth Report, Committee on Government Operations, FDA's Regulation of the New Drug Merital, 8 July (Washington: US Government Printing Office).
82. Van Zwanenberg, Patrick & Erik Millstone (2000) Beyond Skeptical Relativism: Evaluating the Social Constructions of Expert Risk Assessments, Science, Technology, & Human Values 25: 259-82.
83. Vaughan, Diane (1996) The Challenger Launch Decision (Chicago, IL: University of Chicago Press).
84. Wardell, William (1973) Introduction of New Therapeutic Drugs in the US and Great Britain, Clinical Pharmacology and Therapeutics 14: 773-90.
85. Weinberg, Alvin M. (1985) Science and its Limits, Issues in Science and Technology 2: 59-72.